#Serotonin_Reuptake_Inhibitors

  1. Interpersonal sensitivity and response to selective serotonin reuptake inhibitors in patients with acute major depressive disorder
  2. How do we determine whether antidepressants are useful or not?
  3. Influence of baseline severity on the effects of SSRIs in depression: An item-based, patient-level post-hoc analysis
  4. Early symptom non-improvement and aggravation are associated with the treatment response to SSRIs in MDD: A real-world study
  5. Great boast, small roast on effects of selective serotonin reuptake inhibitors: Response to a critique of our systematic review
  6. Efficacy of selective serotonin reuptake inhibitors in the absence of side effects: A mega-analysis of citalopram and paroxetine in adult depression
  7. Cross-sectional networks of depressive symptoms before and after antidepressant medication treatment
  8. Tricyclic and selective serotonin-reuptake-inhibitor antidepressants compared with placebo in randomized trials for acute major depression
  9. Selective serotonin reuptake inhibitors versus placebo in patients with major depressive disorder A systematic review with meta-analysis and Trial Sequential Analysis
  10. Efficacy of selective serotonin reuptake inhibitors and adverse events: Meta-regression and mediation analysis of placebo-controlled trials
  11. The impact of chronic depression on acute and long-term outcomes in a randomized trial comparing selective serotonin reuptake inhibitor monotherapy versus each of 2 different antidepressant medication combinations
  12. Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: Results from the CO-MED trial
  13. Evidence-based somatic treatment of depression in adults
  14. Review of The emperor's new drugs: Exploding the antidepressant myth
  15. Baseline anxiety effect on outcome of SSRI treatment in patients with severe depression: Escitalopram vs paroxetine
  16. Selective serotonin reuptake inhibitors for unipolar depression: A systematic review of classic long-term randomized controlled trials
  17. How often do SSRIs and other new-generation antidepressants lose their effect during continuation treatment? Evidence suggesting the rate of true tachyphylaxis during continuation treatment is low
  18. Publication bias in systematic reviews
  19. Early Onset of Selective Serotonin Reuptake Inhibitor Antidepressant Action
  20. Escitalopram maintenance treatment for prevention of recurrent depression: A randomized, placebo-controlled trial
  21. Efficacy and tolerability of tricyclic antidepressants and SSRIs compared with placebo for treatment of depression in primary care: A meta-analysis
  22. Two items on the Hamilton Depression rating scale are effective predictors of remission: Comparison of selective serotonin reuptake inhibitors with the combined serotonin/norepinephrine reuptake inhibitor, venlafaxine
  23. Fixed-dose trial of the single isomer SSRI Escitalopram in depressed outpatients
  24. Response and remission rates in different subpopulations with major depressive disorder administered venlafaxine, selective serotonin reuptake inhibitors, or placebo
  25. Efficacy of SSRIs and newer antidepressants in severe depression: Comparison with TCAs